Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Peritoneal Neoplasms × pasireotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 4 Pituitary Neoplasms 4 Pancreatic Neoplasms 4 Neuroendocrine Tumors 4 Gastro-enteropancreatic neuroendocrine tumor 3 Carcinoid Tumor 3 Pituitary ACTH Hypersecretion 2 Neoplasms 2 Neoplasm Metastasis 2 Nelson Syndrome 2 Acromegaly 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Small Cell Lung Carcinoma 1 Serotonin Syndrome 1 Sarcoma, Synovial 1 Prolactinoma 1 Prolactin-Producing Pituitary Tumor 1 Primary Inoperable Thymoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peritoneal Neoplasms 1 Pancreatic Fistula 1 Neuroectodermal Tumors, Primitive 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Meningioma 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma 1 Liver Neoplasms 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 21 Paclitaxel 20 Cisplatin 17 Cytoreduction Surgical Procedures 16 Oxaliplatin 13 Carboplatin 12 Fluorouracil 9 Bevacizumab 9 Mitomycin 6 Doxorubicin 6 Leucovorin 5 Docetaxel 5 Surgical Procedures, Operative 4 Neoadjuvant Therapy 4 Blood Specimen Collection 4 sodium thiosulfate 3 catumaxomab 3 Gemcitabine 3 Drug Therapy 3 Chemotherapy, Adjuvant 3 130-nm albumin-bound paclitaxel 3 relacorilant 2 pembrolizumab 2 olaparib 2 nintedanib 2 liposomal doxorubicin 2 Taxes 2 Palliative Care 2 Observation 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04826432 2024-02-08

PASIREOCHIP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡